LEGION™ Revision Metal Hypersensitivity Study

NCT ID: NCT02412813

Last Updated: 2016-03-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, randomized, multi-center, metal hypersensitivity study comparing OXINIUM and cobalt chrome femoral components in subjects with failed total knee arthroplasty (TKA).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 230 subjects will be randomized (1:1) to receive either an OXINIUM or cobalt chrome femoral components as part of their LEGION revision procedure. The objective of this study is to assess a lower serum metal ion concentration level in at least one of the three major mLTTs (Co, Cr or Ni) over 5 years in subjects receiving OXINIUM versus Cobalt Chrome femoral components as part of the LEGION Revision Total Knee System.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Total Knee Replacement Revision

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LEGION OXINIUM femoral component

Group Type ACTIVE_COMPARATOR

LEGION OXINIUM

Intervention Type DEVICE

Investigational Group

LEGION Cobalt Chrome femoral components

Group Type ACTIVE_COMPARATOR

LEGION Cobalt Chrome

Intervention Type DEVICE

Control Group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LEGION OXINIUM

Investigational Group

Intervention Type DEVICE

LEGION Cobalt Chrome

Control Group

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is skeletally mature
* Subject is willing to sign and date an IRB/EC approved consent form
* Subject is a candidate for a revision knee replacement
* Subject has met an acceptable preoperative medical clearance and is free or treated for cardiac, pulmonary, hematological, infection, or other conditions that would pose excessive operative risk
* Subject agrees to adhere to the 10-year study visit schedule

Exclusion Criteria

* Subject with a known metal hypersensitivity
* Subject requires a known bilateral revision TKA
* Subject has severe pronation of the ipsilateral foot or any other relevant clinical condition contributing to abnormal ambulation
* Subject has active infection or sepsis (treated or untreated)
* Subject with an immunosuppressive disorder
* Subject has presence of malignant tumor, metastatic, or neoplastic disease
* Subject has conditions that may interfere with the TKA survival or outcome (i.e., Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease)
* Subject has had intra-articular corticosteroid therapy (or any other intra-articular therapy) in the study knee within 3 months of study enrollment
* Subject has inadequate bone stock to support the device and would require significant augmentation to correct the joint Female subject is of child-bearing age and unwilling to use an approved method of contraception
* Subject has an emotional or neurological condition that would pre-empt their ability or willingness to comply with the study
* Subject is severely overweight (BMI\>40)
* Subject is currently enrolled in another investigational drug, biologic, or device study or has been treated with an investigational product in the past 30 days
* Subject is facing current or impending incarceration
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Smith & Nephew, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thomas Turgeon, MD

Role: PRINCIPAL_INVESTIGATOR

Orthopaedic Innovation Centre

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rothman Institute

Egg Harbor, New Jersey, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

Orthopaedic Innovation Centre

Winnipeg, Manitoba, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

13-4050-05

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nickel Sensitivity
NCT04058743 TERMINATED NA
NitrX Total Knee Arthroplasty RSA
NCT05151315 ACTIVE_NOT_RECRUITING NA